Cargando…

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

BACKGROUND: Retrospective studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors (ICIs). We compared the incidence of HPD during treatment with nivolumab±ipilimumab versus natural tumor progression with placebo in post hoc analyse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Yoon-Koo, Reck, Martin, Nghiem, Paul, Feng, Yan, Plautz, Gregory, Kim, Hye Ryun, Owonikoko, Taofeek K, Boku, Narikazu, Chen, Li-Tzong, Lei, Ming, Chang, Han, Lin, Wen Hong, Roy, Amit, Bello, Akintunde, Sheng, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983994/ https://www.ncbi.nlm.nih.gov/pubmed/35383114 http://dx.doi.org/10.1136/jitc-2021-004273

Ejemplares similares

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
por: Brown, Landon C., et al.
Publicado: (2021)

Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
por: Klein, Oliver, et al.
Publicado: (2021)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
por: Atkins, Michael B, et al.
Publicado: (2023)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

CD11b(+)CTLA4(+) myeloid cells are a key driver of tumor evasion in colorectal cancer
por: Imazeki, Hiroshi, et al.
Publicado: (2021)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
por: Altan, Mehmet, et al.
Publicado: (2023)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
por: Wagner, Michael J, et al.
Publicado: (2021)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
por: Lai, Anne Y, et al.
Publicado: (2020)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
por: Sinha, Meenal, et al.
Publicado: (2021)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response
por: de Sousa, Luana Guimaraes, et al.
Publicado: (2022)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i839351lu1hslavj3606qpr6lg